In NSCLC, cell-cycle gene alterations (CDK4/6 or CCND/E1 amplifications, CDKN2A loss or Rb mutations) have been associated with worse outcome [26,27]. The gene discussed is CDKN2A; the disease is non-small cell lung carcinoma.